Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONStandard

AMPICILLIN AND SULBACTAM

AMPICILLIN SODIUM; SULBACTAM SODIUM

Standard Dose
EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview AMPICILLIN AND SULBACTAM is listed in Drugs@FDA under application 202197 (ANDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient AMPICILLIN SODIUM; SULBACTAM SODIUM Form and strength INJECTABLE;INJECTION - EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL Sponsor ONESOURCE SPECIALTY Submission history Latest submission status date: 2019-11-21 00:00:00.

Structured Monograph

Clinical summary

Approval overview AMPICILLIN AND SULBACTAM is listed in Drugs@FDA under application 202197 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient AMPICILLIN SODIUM; SULBACTAM SODIUM Form and strength INJECTABLE;INJECTION - EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL Sponsor ONESOURCE SPECIALTY Submission history Latest submission status date: 2019-11-21 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.